+ /IL-17 + cells were located at superficial laminae of spinal dorsal horn. This was accompanied by significant upregulation of IL-17. Furthermore, the mRNA expression levels of IL-1β and IL-6 were also significantly enhanced in model rats compared with the sham and control groups in the spinal dorsal horn. In vitro, the proliferation ability and secretion of proinflammatory cytokines notably increased in the IL-17-stimulated astrocytes. Results from the present study indicate that IL-17 may contribute to neuropathic pain by promoting the proliferation of astrocytes and secretion of proinflammatory cytokines in spinal nerve ligation-induced neuropathic pain.
Introduction
Neuropathic pain, defined as pain due to a lesion or disease of the somatosensory system (1) , is one of the most severe forms of chronic pain. It may be induced by nerve trauma, infection, metabolic disease, ischemia, radiotherapy or chemotherapy. It is often refractory to current treatments, partially due to incomplete understanding of the underlying mechanisms. Nerve injury or disease may result in chronic central neuroinflammation in the dorsal horn of the spinal cord and along the pain pathways to the thalamus and the parietal cortex (2, 3) . Central neuroinflammation modulates synaptic plasticity and facilitates nociceptive signal transmission, which eventually develops into chronic pain (4, 5) . Extensive evidence now indicates glial cells are critical in central neuroinflammation following nerve injury (6) (7) (8) . The activation of astrocytes may explain the long-lasting behavioral hypersensitivity (9, 10) .
Astrocytes are the most abundant glial cells in the central nervous system (CNS), and were historically regarded as support cells. However, previous data indicates that astrocytes have multiple active roles in acute and chronic neuronal diseases, including seizure, stroke, and ischemia (9, 11, 12) . Furthermore, accumulating evidence has demonstrated that astrocytes are important for maintenance of neuropathic pain (7, 9, 10) . In all models of neuropathic pain, such as rhizotomy (8) , chronic constriction injury (13) and spinal nerve ligation (14) , proliferation and activation of astrocytes has been demonstrated, and inhibiting astrocytes in the spinal cord was demonstrated to reduce neuropathic pain (13, 14) . However, the activation of astrocytes and how they mediate neuropathic pain requires further elucidation.
Interleukin-17A (IL-17) is the first member of a family of cytokines, designated IL-17A-F, which are predominantly produced by activated cluster of differentiation (CD)4 + T cells. IL-17 has potent proinflammatory properties and it is involved in modulating the immune response in inflammatory disorders (15 (20) and in peripheral nerve injured models (2, 18) . These previous studies suggest peripheral IL-17 exerts an effect in inflammatory and neuropathic pain. Intrathecal injection of recombinant IL-17 promotes thermal hyperalgesia of normal mice (20) , which demonstrates that central IL-17 is a key factor in inflammatory pain. The role of IL-17 in the CNS in models of neuropathic pain was suggested by CD4 + T cell infiltration (21) , and its elevated concentration in the spinal cord following nerve injury (22). In addition, inflammatory disorders that are associated with IL-17 and Th17 cells, including multiple sclerosis (MS) or allergic encephalomyelitis, often result in the development of neuropathic pain (23) . However, the specific role of central nerve system IL-17 in nerve injury-induced neuropathic pain has not been extensively investigated.
The aim of the present study was to determine whether IL-17 was highly expressed in the spinal cord and investigate which cell produced it during the maintenance phase of neuropathic pain. The association between IL-17 and astrocytes was also investigated by analyzing the biological characteristics of IL-17-stimulated astrocytes in cell proliferation and secretion of proinflammatory cytokines in vitro.
Materials and methods

Animals.
A total of 116 male Sprague-Dawley rats (age, 8-10 weeks; weight, 180-250 g) were obtained from the Experimental Animal Center of Jiangsu University (Zhenjiang, China) and acclimatized to the environment for at least 1 week prior to use in the experiments. The environment was maintained at a constant room temperature and humidity level (22˚C; relative humidity, 40-60%). All rats were housed with access to food and water ad libitum and maintained in a 12:12 h light/dark cycle. The well-being of the animals was monitored daily. All animal experiments were approved by the Animal Care and Ethics Committee of Jiangsu University.
Ligation of L5 and L6 spinal nerves. Surgery was performed according to the method described previously (24) . Briefly, rats were anesthetized with pentobarbital sodium (50 mg/kg i.p.) and a longitudinal incision overlying the lumbar (L)4-sacral (S)1 section was made and the left muscle tissue was separated. The L6 transverse process and L6/S1 posterior interarticular process were exposed and transected. The L5 and L6 spinal nerve was carefully exposed and the distal nerve of L5 and L6 were gently separated, firmly ligated with 5-0 silk suture and transected. The wound was irrigated with sterile saline and inspected for homeostasis, and closed. Sham surgery was performed identically, however, the nerves were not ligated. The animals were allowed to emerge from anesthesia in the warming place. The naive group did not undergo an operation.
Testing mechanical sensitivity. The animals were habituated to the behavioral testing apparatus for 30 min to 1 h prior to testing. The testing environment was kept quiet and all tests were conducted in the morning between 8:30 and 11:30. (25) . The von Frey filament was presented perpendicular to the plantar surface with sufficient force to result in slight buckling against the paw for ≤8 sec. Paw withdrawal was considered a positive response. The 50% mechanical withdrawal threshold (50% MWT) was calculated. If the value of 50% MWT exceeded 4.0 g at day 7 post-surgery, the animal model was considered a failed preparation and excluded from the experiment. A total of 8 rats were included in each group. The person performing the behavioral tests was blinded to the experimental groups.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Rats were deeply anesthetized by inhalation of isoflurane (4%) in 100% O 2 and intracardially perfused with 0.9% saline (between 200 and 250 ml per rat at 4˚C), and the spinal cords were subsequently harvested. The lumbar spinal dorsal horns from the L5 to L6 ipsilateral to injury were dissected and rapidly frozen. The tissues were homogenized and total RNA was extracted with TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). In the in vitro experiment, total RNA was extracted from astrocytes with 100 ng/ml IL-17 (R&D Systems, Inc., Minneapolis, MN, USA) treatment for three days or without. Interleukin-6 (IL-6), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and/or IL-17 mRNA were measured by RT-qPCR. RT-qPCR was performed with the Verso 1-step RT-qPCR kit, SYBR Green, low ROX (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol and the thermocycling conditions were as follows: 5 min at 94˚C; followed by 35 cycles of 10 sec at 94˚C, 5 sec at 50˚C, and 10 sec at 72˚C. Relative expression was calculated with normalization to β-actin values (26) . The primers used are presented in Table I .
Immunohistochemistry staining. Rats were deeply anesthetized by inhalation of isoflurane (4%) in 100% O 2 and intracardially perfused with 0.9% saline (between 200 and 250 ml per rat at 4˚C), followed by 4% formaldehyde in 0.1 M phosphate-buffered saline (PBS; between 300 and 350 ml per rat). The L5 segment of lumbar spinal cord was harvested, postfixed overnight in 4% formaldehyde and then dehydrated in 30% sucrose for at least 72 h at 4˚C. Tissue was then freeze-mounted in optimal cutting temperature embedding medium (Sakura Finetek USA, Inc., Torrance, CA, USA) on cork blocks for cryostat sectioning. Spinal cords were sectioned transversely at a thickness of 20 µm. The sections were washed three times with PBS. Sections were then blocked for 1 h at 37˚C with blocking solution [PBS containing 5% bovine serum albumin (BSA; Shanghai Universal Biotech Company, Shanghai, China) and 0.25% Triton X-100] followed by incubation with the primary antibody diluted in PBS containing 1% BSA at 4˚C overnight. Primary antibodies used were as follows: Monoclonal purified goat anti-rat CD4 molecular complex antibody (1:100; Santa Cruz Biotechnology, Inc., Dallas, TX, USA; cat. no. sc-1140) for the detection of infiltrating CD4 + cells; rabbit anti-rat IL-17 (1:100; Santa Cruz Biotechnology, Inc.; cat. no. sc-7927); and mouse anti-rat glial fibrillary acidic protein (GFAP, 1:1,000; Santa Cruz Biotechnology, Inc.; cat. no. sc-135921) for the detection of astrocytes. The sections were then washed five times with PBS and incubated with the appropriate secondary antibody for 1 h at room temperature. Secondary antibodies used were as follows: Fluorescein isothiocyanate (FITC)-conjugated donkey anti-goat (1:100; Santa Cruz Biotechnology, Inc.; cat. no. sc-2042), phycoerythrin (PE)-conjugated donkey anti-rabbit (1:100; Santa Cruz Biotechnology, Inc.; cat. no. sc-3745), and PE-conjugated goat anti-mouse (1:250; Invitrogen; Thermo Fisher Scientific, Inc.; cat. no. M30004). Following washing with PBS, the sections were stained with Hoechst 33258 at 37˚C for 5 min and the cells were examined with a fluorescence microscope (Olympus BX51; Olympus Corporation, Tokyo, Japan).
Fluorescence-activated cell sorting (FACS) was used to detect the infiltrated CD4
+ T cells in spinal cord. The ipsilateral (relative to injury) lumbar dorsal horns of L5-L6 spinal cord were harvested as described above. Mononuclear cells from the spinal cord tissue were obtained with discontinuous Percoll gradients method following a previously described method (27) . Due to the limited numbers of mononuclear cells from a single animal, each FACS sample was prepared from three spinal cords pooled together. The collected mononuclear cells was suspended in 100 µl PBS containing anti-rat CD3-FITC (1:100; eBioscience, Inc., San Diego, CA, USA; cat. no. 11-0030) and anti-rat CD4-PE (1:100; eBioscience, Inc.; cat. no. 12-0040). Cells were incubated at 4˚C for 30 min. Following washing twice with PBS, all stained cells were resuspended in 4% formaldehyde/PBS at 4˚C overnight. Data were acquired by flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA) and analyzed using CellQuest software (version 2.8; BD Biosciences).
ELISA for serum IL-17. Serum IL-17 was measured by an ELISA kit (Rat IL-17A Platinum ELISA; eBioscience, Inc.) following the manufacturer's protocols. All samples were measured in triplicate, and the mean concentration was calculated from the standard curve.
Astrocyte culture and cell proliferation assay. As previously described (28) , astrocyte cultures were prepared from 1-2 day-old postnatal rats. Briefly, in a sterile environment, spinal cords were dissected and cell suspensions were prepared. These were subsequently transferred to culture flasks and incubated at 37 ˚C in a CO 2 balanced incubator. After 7 days, the flask was agitated at 200 rpm at 37˚C overnight to remove oligodendrocytes, neurons, and microglial cells. Following three passages, the astrocytes were divided into IL-17-stimulated and naive groups. Briefly, 1x10
3 cells/well were seeded into 96-well plates in Dulbecco's modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc.) and following cell adherence to the plate, IL-17 was added to the wells at concentration of 10, 50 or 100 ng/ml, and incubated at 37˚C for 24-72 h. Subsequently, 10 µl (5 mg/ml) MTT was added to each well and the plate was further incubated for 4 h to deoxidize MTT under light-blocking conditions. Following removal of the MTT dye solution, the cells were treated with 100 µl DMSO and the absorbance at a wavelength of 490 nm was measured using the ELx800 UV microplate reader (BioTek Instruments, Inc., Winooski, VT, USA). Cells from the naive group were not stimulated by IL-17.
Statistical analysis. All data were expressed as the mean ± standard deviation. Figures and statistical analyses were made with GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). For comparison of mechanical sensitivity, spinal inflammatory cytokines, infiltrated-cellular phenotypes in the spinal cord and the MTT assay, appropriate two-way analysis of variance was performed followed by Bonferroni's multiple comparison post-hoc test. Immunohistochemistry data were analyzed by t-test or one-way analysis of variance. Inflammatory cytokines data in vitro were evaluated using t-test. P<0.05 was considered to indicate a statistically significant difference.
Results
Behavioral mechanical sensitivity of rats following L5/L6
spinal nerve ligation. The mechanical sensitivity (indicated by the 50% threshold force for paw withdrawals) was measured in the injured ipsilateral hind paws prior to (baseline values) and up to 2 weeks after surgery. Baseline values were not different between the groups. Following SNL, rats developed pain hypersensitivity at day 3 up to day 14 compared with the other two groups. Furthermore, no significant differences were observed between the sham group and the control group at any time point (Fig. 1) .
CD4
+ Th17 cell infiltration was observed in the ipsilateral dorsal horn following L5-L6 spinal cord ligation. Following spinal nerve ligation, IL-17 mRNA increased significantly in the ipsilateral dorsal horn of L5-L6 spinal cord at day 7 (P<0.05). No differences were detected between the sham and control group at any time ( Fig. 2A) . Serum IL-17 in naive, sham-operated, and SNL rats at days 7 and 14 post-surgery was analyzed by ELISA to determine whether the changes of IL-17 in spinal cord was associated with the changes in the peripheral serum. Though spinal nerve ligation induced a moderate increase in IL-17 expression, no differences were determined amongst the three groups at any time point (Fig. 2B) . Furthermore, IL-17 localization was detected in the spinal cord at day 7 after surgery. As IL-17 is preferentially expressed by CD4 + T cells, double immunofluorescence labeling was used to demonstrate that IL-17 immunoreactivity was colocalized with CD4 in the ipsilateral dorsal horn, and the immunostaining density of IL-17 and CD4 markedly increased when compared with the sham-operated rats (Fig. 2C) .
To further confirm IL-17 was produced by spinal cord-infiltrating CD4 + T cells, CD4 + T cells were detected in the lumbar spinal cord using FACS at days 7 and 14 post-surgery. SNL induced a significant increase in the infiltration of CD4 + T cells into the ipsilateral side of lumber spinal cord at day 7 (P<0.001), while no marked changes were observed at day 14 compared with the naive and sham groups (Fig. 2D) .
Astrocyte activation was observed in spinal dorsal horn accompanying proinflammatory cytokine increases following SNL.
SNL was demonstrated to induce marked expression of GFAP at the ipsilateral side compared with either the contralateral spinal cord or either side of the sham group. The level of GFAP in the ipsilateral side was consistent with the contralateral side in the sham group. GFAP activation was predominantly localized to the superficial laminae of the lumbar spinal dorsal horn. The immunoreactivity of GFAP notably increased compared with the sham-operated rats (Fig. 3A) . Furthermore, the qPCR indicated significant increases in the expression levels of IL-6 and IL-1β in the ipsilateral spinal dorsal horn following SNL at day 7 (P<0.05 and P<0.01) and IL-6 remained at high levels at day 14 (P<0.05; Fig. 3B and C) . No change in expression of TNF-α was demonstrated at days 7 and 14 in all groups (data not shown).
IL-17 promoted the proliferation of astrocytes and the expression of proinflammatory cytokines in vitro.
To investigate the effect of IL-17 on astrocytes, 10, 50 or 100 ng/ml IL-17 was used to stimulate astrocytes in vitro. The results of the MTT assay demonstrated that astrocytes proliferated successively over time, but not significantly higher than that at 24 h in each group. IL-17 induced significant astrocyte proliferation at 48 h compared with the naive group (P<0.05). However, at 72 h, only 100 ng/ml IL-17 significantly promoted proliferation (P<0.01; Fig. 4A) . Thus, the expression levels of IL-1β, IL-6 and TNF-α mRNA at 72 h between the group with 100 ng/ml IL-17 stimulation and the naive group were investigated. Treatment with 100 ng/ml IL-17 elevated IL-1β and IL-6 mRNA expression levels (Fig. 4B) , but not TNF-α (data not shown). These results demonstrate that IL-17 enhanced astrocytic activity.
Discussion
Damage to a peripheral nerve results in activity from microglial and astrocytic cells, in addition to infiltration of macrophages and T cells in the CNS. These non-neuronal cells can sensitize neurons in nociceptive pathways by release of pronociceptive factors, including cytokines and chemokines, which is an important factor underlying the pathogenesis of neuropathic pain (29) . Nerve injury induced behavioral hypersensitivity can be divided into at least two phases, an initiation phase (from day 0 to day 5) and a maintenance phase (after day 5) based on the pattern of nociceptive behaviors and the animals' responses to selective treatment with therapeutic agents. The spinal cord is an important gateway through which peripheral pain signals are transmitted to the brain. The results of the present study determined proinflammatory IL-17 contributed to the persistence of tactile hypersensitivity following nerve injury.
IL-17 is typically produced by immune cells, including Th17, γδT cells and natural killer T cells, CD8 + T cells (30) . The present study determined that IL-17 increases in the ipsilateral spinal cord dorsal horn at day 7 post-SNL and observed IL-17 is located in CD4 + cells via double immunostaining. Previous studies have detected CD4 + cells in the lumbar spinal cord or dorsal root ganglia in animal models of neuropathic pain (21, 31) and demonstrated these CD4-expressing cells were predominantly CD4 + T cells (21) . The current study confirmed CD4 + T cell infiltration in the spinal cord at day 7 post-nerve injury. The temporal profile of CD4 + T cells is consistent with IL-17 expression in the spinal cord. Furthermore, ELISA demonstrated the high level of IL-17 in the spinal cord following SNL did not come from the peripheral serum. These results suggested IL-17 was produced by Th17 cells. However, a previous study suggested spinal cord-infiltrating CD4 + T cells are Th1 cells (32) . The inconsistency between that and the present study may be associated with the differences in species (rats in the present study, as compared with mice) and method of detection. In addition, Th17 helper cells are not the only cells capable of producing IL-17. In the CNS, expression of IL-17 was also demonstrated in astrocytes located in the active areas of MS lesions (23) , or in spinal dorsal horn during CFA-induced inflammatory pain (19) . To the best of our knowledge, there are no previous studies regarding the expression of CD4 by astrocytes in Numerous experimental studies suggest that IL-17 is important in a wide range of inflammatory diseases, including autoimmune diseases, such as MS, and other nonimmune neuroinflammatory processes, such as stroke and cerebral ischemia-reperfusion injury (15) (16) (17) (18) 35) . However, its tissue-specific mechanism remains unclear. A previous study demonstrated recombination-activating gene 1 KO mice lacking functional IL-17-producing T lymphocytes exhibited reduced thermal hyperalgesia due to impaired recruitment of macrophages and expression of macrophage chemoattractant protein in the sciatic nerve following chronic constriction injury, which provided initial evidence of the involvement of IL-17 in neuropathic pain (36) . In addition, a previous study reported IL-17 KO mice presented with reduced mechanical allodynia and decreased (2) . The results of the immunostaining in the present study indicated that the majority of IL-17 is located in the superficial zone of the ipisilateral spinal dorsal horn, which is also the region of notable astrocytic activation. It is well known that astrocytes constitutively express the receptor of IL-17A (37) . Thus, it is reasonable to suggest that IL-17 activates local astrocytes and induces glial response, such as production of proinflammatory cytokines. This possibility is supported by in vitro results from the present study, which demonstrate, in addition to proliferation, stimulation of resting astrocytes by IL-17 increases expression of IL-1β and IL-6, which also occurs in vivo. These mediators lead to central sensitization and pain hypersensitivity (29, 38, 39) . The finding that IL-17 stimulates astrocytes to produce proinflammatory mediators is also demonstrated in MS, experimental autoimmune encephalomyelitis and ischemic brain injury (12, 40) . However, activation of spinal astrocytes subsequent to nerve injury was not entirely explained by IL-17 and IL-6 expression remained high at day 14 post-SNL and astroglia activation persisted for longer than seven days (7, 9, 10) , which suggests that IL-17-mediated signaling, although important, is not the only mechanism underlying astroglia activation and that there may be independent and/or cooperative mechanisms involving other signals. In addition, Meng et al (20) reported that spinal IL-17 facilitated inflammatory pain by enhancing phosphorylated-NR1 of the N-methyl-D-aspartate receptor in CFA-injected rats. Furthermore, IL-17 can stimulate microglia to upregulate the production of proinflammatory mediators, such as CXCL2, IL-6, and neurotrophic factors (41) , and increase the permeability of BBB in vitro to promote infiltration of proinflammatory cytokines and CD4 + T cells in the CNS. According to these findings, it is possible that other mechanisms may be involved in spinal IL-17-mediated neuropathic pain.
In conclusion, the present study demonstrated that IL-17 is involved in maintaining neuropathic pain, due to activation of astrocytes and the secretion of proinflammatory cytokines. Elevated IL-17 may be produced by infiltrated CD4 + T cells. However, previous research on IL-17-mediated disorders in the CNS demonstrated cross-interaction between IL-17 and other factors is likely to be involved in the pathogenesis of neuropathic pain. Future studies are required to further investigate and design novel therapies for patients with neuropathic pain. 
